Introduction {#s1}
============

In the drug discovery process, plants still remain an invaluable source of drugs and drug leads. They possess enormous structural and chemical diversity that is not matched by any synthetic libraries of small molecules ([@B118]). As pharmacological activities of chemicals are generally structure dependent, the structural and chemical diversity is obviously an advantage. Over the last decade, the interest in (iso)flavonoids strongly increased. Especially the prenylated forms moved into the focus because of their versatile and promising pharmacological properties and health benefits on multitarget tissues ([@B60]; [@B17]). Prenylated isoflavonoids have increased lipophilicity as compared to nonprenylated forms, leading to high affinity with cell membranes and enhanced biological activities or significant pharmacological effects ([@B17]; [@B119]). These compounds offer a multitude of biological activities, which justify major and much deeper pharmacological investigation ([@B12]). Accordingly, there is a recent in-depth investigation of prenylated flavonoids as promising anticancer, anti-inflammatory, antioxidant, and neuroprotective nutraceuticals ([@B145]; [@B133]), with the prenyl substituent playing a key role in the molecular activity. Prenylated flavonoids are found predominantly in the Leguminosae family, although the phenyl-propanoid pathway---necessary for their production---is ubiquitously present in plants including nonleguminous families ([@B109]; [@B64]).

Alpinumisoflavone (AIF) or \[5-hydroxy-7-(p-hydroxyphenyl)-2,2-dimethyl-2H-6H-benzo-\[1,2-b:5,4-b\]dipyran-6-one\] is a dimethylpyrano derivative prenylated at ring A of genistein ([**Figure 1**](#f1){ref-type="fig"}). It is a major constituent of *Derris eriocarpa* F.C. How, commonly referred as "Tugancao" in "Zhuang" and "Dai" ethnomedicine in Guangxi and Yunnan Province of China ([@B42]). A high content of AIF was reported in fully mature fruits (mandarin melon berry) of *Cudrania tricuspidata* Bur. ex Lavallee (syn. *Maclura tricuspidata* Carrière) ([@B121]), a crop cultivated in East Asia ([@B144]; [@B120]), Europe and America ([@B80]) for its fruits and timber, and with an immense medicinal and economic value ([@B143]). Isolated for the first time by [@B53], AIF was identified in many medicinal plants widely used over the world ([**Table 1**](#T1){ref-type="table"}). Although data depicted in this table are not exhaustive, the global trend is in accordance with [@B13] who reported that prenylated flavonoids occur mostly in Leguminosae and Moraceae, with few detected in other families. Over the last two decades, the body of literature of AIF and its pharmacological potential is steadily growing. This review summarizes and gives a critical look on the current knowledge of the biological activities, therapeutic potential, and mechanism of action of AIF.

![Chemical structures of isoflavone, genistein, alpinumisoflavone, and some of its derivatives.](fphar-10-00952-g001){#f1}

###### 

Sources and biological and/or pharmacological activities of alpinumisoflavone.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family                                                          Plant species                        Plant parts                                                                     Origin/city (country)                                                                                                          Biological and/or pharmacological activity                                                                                    References
  --------------------------------------------------------------- ------------------------------------ ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------- ------------
  **Leguminosae**                                                 *Crotalaria bracteata*               Roots and stems                                                                 Roi-Et\                                                                                                                        Cytotoxicity against MCF-7 and NCI-H187 cell lines (inactive)                                                                 [@B123]
                                                                                                                                                                                       (Thailand)                                                                                                                                                                                                                                                   

                                                                  *Erythrina caffra* Thunb.            Stem bark                                                                       KwaZulu-Natal\                                                                                                                 Anti-bacterial activity against *Staphylococcus aureus*, *Bacillus subtilis*, *Klebsiella pneumonia* and *Escherichia coli*   [@B18]
                                                                                                                                                                                       (South Africa)                                                                                                                                                                                                                                               

  *Erythrina indica*                                              Stem bark                            Ibadan (Nigeria)                                                                *C*ytotoxicity against KB cells                                                                                                [@B95]                                                                                                                        

  *Erythrina lysistemon*                                          Stem bark                            --\                                                                             Estrogen-like effects in a menopause model of\                                                                                 [@B86]; [@B85]; [@B87]                                                                                                        
                                                                                                       (Zimbabwe)                                                                      ovariectomized Wistar rats                                                                                                                                                                                                                                   

  *Erythrina mildbraedii*                                         Root bark                            Buea\                                                                           Inhibition of protein tyrosine phosphatase-1B (PTP1B)                                                                          [@B88]                                                                                                                        
                                                                                                       (Cameroon)                                                                                                                                                                                                                                                                                                                                   

  *Erythrina orientalis*                                          Stem bark                            Kunir Kidul (Indonesia)                                                         Cytotoxicity against murine leukemia P-388 cells\                                                                              [@B126]                                                                                                                       
                                                                                                                                                                                       Radical scavenging activity using DPPH (2,2-diphenyl-1-picrylhydrazyl)                                                                                                                                                                                       

  *Erythrina ovalifolia* Roxb.                                    Stem bark                            Kunir Kidul (Indonesia)                                                         Antiplasmodial activity against *Plasmodium falciparum*                                                                        [@B127]                                                                                                                       

  *Erythrina poeppigiana*                                         Stem bark                            Sancta Cruz (Bolivia)                                                           Estrogen-like effect in U2OS human osteosarcoma cells through ERs-dependent reporter gene activity                             [@B33]; [@B34]                                                                                                                

  *Erythrina senegalensis* DC                                     Stem bark                            Foumban (Cameroon)                                                              Inhibition of the HIV-1 Protease                                                                                               [@B65]                                                                                                                        

  Phospholipase Cγ1inhibitory activity (inactive)\                [@B101]\                                                                                                                                                                                                                                                                                                                                                                          
  Inhibition of acyl CoA:diacylglycerol acyltransferase           [@B100]                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  *Erythrina stricta* Roxb.                                       Stem bark                            Nagaland\                                                                       Antimicrobial and radical scavenging (DPPH) activities                                                                         [@B1]                                                                                                                         
                                                                                                       (India)                                                                                                                                                                                                                                                                                                                                      

  *Erythrina suberosa* Roxb.                                      Stem bark                            Jammu\                                                                          Cytotoxicity against human myeloid leukemia cell lines HL-60 and K-562 and T lymphoblastic cell line MOLT-4\                   [@B61]                                                                                                                        
                                                                                                       (India)                                                                         Apoptotic potential in HL-60 cells                                                                                                                                                                                                                           

  *Erythrina variegate* L.                                        Stem bark                            Dhaka\                                                                          Radical scavenging (DPPH) activity                                                                                             [@B107]                                                                                                                       
                                                                                                       (Bangladesh)                                                                                                                                                                                                                                                                                                                                 

  **Leguminosae**                                                 *Derris eriocarpa*                   --                                                                              --                                                                                                                             Inhibition of osteoclast differentiation in vitro and antiosteoporotic effect in ovariectomized mice                          [@B28]

  --                                                              --                                   Suppression of tumor growth and metastasis of clear-cell renal cell carcinoma   [@B138]                                                                                                                                                                                                                                                      

  *Laburnum alpinum* J. Presl.                                    Twigs                                Salford\                                                                        --                                                                                                                             [@B53]                                                                                                                        
                                                                                                       (England)                                                                                                                                                                                                                                                                                                                                    

  *Lonchocarpus glabrescens*                                      --                                   Punchana, (Peru)                                                                Inhibition of the hypoxia-inducible factor-1 (HIF-1) activation in human breast tumor T47D cells                               [@B75]                                                                                                                        

  *Milletia pachycarpa*                                           Stem and leaves                      --                                                                              No estrogenic activity on the β-galactosidase activity in a yeast two-hybrid assay                                             [@B102]                                                                                                                       

  *Millettia taiwaniana*                                          Twigs and leaves                     --\                                                                             Inhibition of the Epstein--Barr virus activation with no cytotoxicity against Raji cells                                       [@B52]                                                                                                                        
                                                                                                       (Singapore)                                                                                                                                                                                                                                                                                                                                  

  *Millettia thonningii* (Schum. et Thonn.) Bak.                  Seeds                                Legon-Accra\                                                                    Antifungal activity against wild-type *Candida albicans* and the reference strain ATCC18804C                                   [@B5]                                                                                                                         
                                                                                                       (Ghana)                                                                                                                                                                                                                                                                                                                                      

  Seeds                                                           Accra\                               Antischistosomal activity against *Schistosoma mansoni*                         [@B76]                                                                                                                                                                                                                                                       
                                                                  (Ghana)                                                                                                                                                                                                                                                                                                                                                                           

  Seeds                                                           --\                                  Antiplasmodial activity against *Plasmodium falciparum*                         [@B56]                                                                                                                                                                                                                                                       
                                                                  (Ghana)                                                                                                                                                                                                                                                                                                                                                                           

  *Sophora moorcroftiana* (Wall.)                                 Aerial parts                         Tibet\                                                                          Antibacterial effects on Meticillin-resistant *Staphylococcus aureus*                                                          [@B137]                                                                                                                       
                                                                                                       (China)                                                                                                                                                                                                                                                                                                                                      

  *Tipuana tipu* (Benth.)\                                        Leaves                               Mansoura (Egypt)                                                                Antiproliferative activity against leukemia \[CCRF-CEM, MOLT-4, and HL-60(TB)\], renal SN12C, and breast MCF-7 cancer cells\   [@B3]                                                                                                                         
  Lillo                                                                                                                                                                                Anti-inflammatory activity in carrageenan-induced rat paw edema model                                                                                                                                                                                        

  **Moraceae**                                                    *Chlorophora tinctoria* (L.) Gaud.   Leaves and twigs                                                                Maynas\                                                                                                                        Fatty acid synthase inhibitory and antifungal activities (inactive)                                                           [@B73]
                                                                                                                                                                                       (Peru)                                                                                                                                                                                                                                                       

  *Cudrania tricuspidata* (Carr.)                                 Fruits                               Cheongju, (Korea)                                                               Inhibition of the mouse brain monoamine oxidase                                                                                [@B43]                                                                                                                        

  Twigs                                                           Anhui (China)                        Tyrosinase inhibition                                                           [@B150]                                                                                                                                                                                                                                                      

  *Ficus bengalensis*                                             Aerial roots                         Sahiwal (Punjab, India)                                                         --                                                                                                                             [@B110]                                                                                                                       

  *Ficus benjamina* var. nuda (Miq.) Barrett                      Fruits                               Honolulu (Hawaii)                                                               --                                                                                                                             [@B30]                                                                                                                        

  *Ficus chlamydocarpa* Mildbraed and Burret                      Root bark\                           Bahouan\                                                                        Antimycobacterial, antibacterial and antifungal activities                                                                     [@B59]                                                                                                                        
                                                                                                       (Cameroon)                                                                                                                                                                                                                                                                                                                                   

  *Ficus glumosa*                                                 Stem bark                            Makenene\                                                                       Cytotoxicity against prostate cancer PC-3 cell line                                                                            [@B91]                                                                                                                        
                                                                                                       (Cameroon)                                                                                                                                                                                                                                                                                                                                   

  *Ficus nervosa*\                                                                                     Pingtung (Taiwan)                                                               --                                                                                                                             [@B16]                                                                                                                        
  Heyne ex Roth.                                                                                                                                                                                                                                                                                                                                                                                                                                    

  *Ficus racemosa*                                                Fruits                               --\                                                                             Inhibition of protein tyrosine phosphatase-1B (PTP1B)                                                                          [@B129]                                                                                                                       
                                                                                                       (Vietnam)                                                                                                                                                                                                                                                                                                                                    

  *Ficus tikoua* Bur                                              *Rhizomes*                                                                                                           Radical scavenging (DPPH) and α-glucosidase inhibitory activities                                                              [@B40]                                                                                                                        

  *Maclura tricuspidata* Carrière (syn.*Cudrania tricuspidata*)   Fruits                               Jinju\                                                                          Cytotoxicity against human neuroblastoma SH-SY5Y cell line                                                                     [@B49]                                                                                                                        
                                                                                                       (South Korea)                                                                                                                                                                                                                                                                                                                                

  **Dilleniaceae**                                                *Tetracera scandens*                 Branch                                                                          --\                                                                                                                            Glucose-uptake induced activity in basal and insulin-stimulated L6 myotubes                                                   [@B66]
                                                                                                                                                                                       (Vietnam)                                                                                                                                                                                                                                                    

  **Apiaceae**                                                    *Azorella madreporica*               Whole plant                                                                     Valle Nevado (Chile)                                                                                                           Antimycobacterial and antibacterial activities (inactive)                                                                     [@B113]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

--‚ not indicated.

Pharmacological Activities {#s2}
==========================

Over the last decade research indicates that prenylation usually renders (iso)flavonoids with improved bioactivities ([@B145]; [@B84]), suggesting that prenylated compounds have a higher potential to be developed and utilized ([@B17]). Focusing on AIF, the following activities have been demonstrated and claimed to be promising by the authors ([**Table 2**](#T2){ref-type="table"}).

###### 

Pharmacological activities of alpinumisoflavone and underlying mechanisms.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pharmacological activities                                         Experimental model                                          Dose/concentration                                                                                                                                                                                                                                                                                                                                                               Mechanism of action                                                                                                                                                                                                                                     References
  ------------------------------------------------------------------ ----------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  Estrogenic activity                                                ER competitor binding assay                                                                                                                                                                                                                                                                                                                                                                                                                  Weak ERα and ERβ binder; higher selectivity for ERα                                                                                                                                                                                                     [@B85]; [@B78]

  ER competitor binding assay                                                                                                    Weak ERα and ERβ binder; higher selectivity for ERβ                                                                                                                                                                                                                                                                                                                              [@B33]                                                                                                                                                                                                                                                  

  U2OS-ERα, U2OS-ERβ human osteosarcoma cells                        10^−9^--10^−6^ M                                            Induction of luciferase reporter gene activity                                                                                                                                                                                                                                                                                                                                   [@B34]; [@B78]                                                                                                                                                                                                                                          

  MCF-7 breast cancer cells                                          10^−9^--10^−6^ M                                            Up-regulation of the expression of estrogen α receptor target genes PCNA, cyclin D1, cyclinE1, cMyc, and LRH-1; downregulation of GREB1 at 10^−9^ M                                                                                                                                                                                                                              [@B78]                                                                                                                                                                                                                                                  

  Ovariectomized Wistar rats                                         0.01, 0.1, and 1 mg/kg daily for 3 days i.p.                Increase in uterine wet weight, and uterine and vaginal epithelial height                                                                                                                                                                                                                                                                                                        [@B85]                                                                                                                                                                                                                                                  

  Ovariectomized Wistar rats                                         1, 10 mg/kg daily for 28 days i.p.                          Increase in uterine and vaginal epithelial height; increase in FSH/LH ratio;\                                                                                                                                                                                                                                                                                                    [@B86]                                                                                                                                                                                                                                                  
                                                                                                                                 reduction in atherogenic risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Ovariectomized Wistar rats                                         0.1, 1, and 10 mg/kg daily for 3 days i.p.                  Down-regulation of Esr1 mRNA expression; upregulation of Cyp7a1 mRNA expression.                                                                                                                                                                                                                                                                                                 [@B87]                                                                                                                                                                                                                                                  

  Antiosteoporotic activity                                          RAW264.7 osteoclast precursor                               2.5 and 5 µM                                                                                                                                                                                                                                                                                                                                                                     Suppression of osteoclast differentiation and proliferation by inhibiting RANKL-induced p38, ERK and JNK activation                                                                                                                                     [@B28]

  Ovariectomy-induced osteoporosis                                   10, 25 mg/kg daily for 6 weeks p.o.                         Prevention of OVX-induced bone loss by increasing BV/TV ratio, Tb.Th and Tb.N while decreasing Tb.Sp in OVX mice                                                                                                                                                                                                                                                                 [@B28]                                                                                                                                                                                                                                                  

  Dexamethasone-induced osteoporosis                                 20, 40 mg/kg daily for 8 weeks p.o.                         Increase in bone mineral density and mineral content of the proximal femur bone in rats; increase in BV/TV ratio, Tb.Th and Tb.N; decrease in Tb.Sp                                                                                                                                                                                                                              [@B139]                                                                                                                                                                                                                                                 

  MC3T3-E1 and MLO-Y4 osteoblasts and osteocytes                     5--20 µM                                                    Reverse of proapoptotic and antiproliferative effects of dexamethasone *via* suppressing Nox2-dependent ROS generation                                                                                                                                                                                                                                                           [@B139]; [@B147]                                                                                                                                                                                                                                        

  Antioxidant activity                                               DPPH assay                                                  IC~50~: 8.30 µg/ml\                                                                                                                                                                                                                                                                                                                                                              DPPH scavenging activity of differing degree                                                                                                                                                                                                            [@B107]; [@B126];\
                                                                                                                                 IC~50~: 708.5 µM\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        [@B40]\
                                                                                                                                 IC~50~: 54.80 µg/ml IC~50~: 54.02 µg/ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [@B11];

  Ferric Reducing Antioxidant Power (FRAP) assay                     35.55 µM trolox equivalents/1.5 mM                          Free radical-scavenging activity\                                                                                                                                                                                                                                                                                                                                                [@B11];                                                                                                                                                                                                                                                 
                                                                                                                                 Increase in the FRAP reducing power                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  LPS-stimulated RAW264.7 cells                                      5, 10 µg/ml                                                 Increase in catalase, HO-1, glutathione peroxidase, and superoxide dismutase production                                                                                                                                                                                                                                                                                          [@B71]                                                                                                                                                                                                                                                  

  Anti-inflammatory activity                                         LPS-stimulated acute lung injury in mice                    1, 5, 10 mg/kg i.p. 1 h before LPS challenge                                                                                                                                                                                                                                                                                                                                     Alleviated lung lesions, pulmonary edema, and hemorrhages: inhibition of myeloperoxidase activity                                                                                                                                                       [@B71]

  LPS-stimulated RAW264.7 cells                                      5, 10 µg/ml                                                 Decreased production of TNF-α, IL-6, IL-1b, ICAM-1, and NO; suppression of NF-κB, MAPKs, and NLRP3 pathways                                                                                                                                                                                                                                                                      [@B71]                                                                                                                                                                                                                                                  

  Carrageenan-induced rat paw edema                                  25 mg/kg i.p. 30 min before λ-carrageenan (unique dose)     Inhibition of edema formation                                                                                                                                                                                                                                                                                                                                                    [@B3]                                                                                                                                                                                                                                                   

  Antimicrobial activity                                             *Mycobacterium smegmatis* MC2 155                           MIC = 19.53 µg/ml\                                                                                                                                                                                                                                                                                                                                                               Growth inhibition                                                                                                                                                                                                                                       [@B59]
                                                                                                                                 MBC = 39.06 µg/ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  *Enterobacter cloacae* LMP1104G\                                   IZ = 15.5--18.7 mm except for *E. coli* (7 mm)\             Growth inhibition                                                                                                                                                                                                                                                                                                                                                                [@B59]                                                                                                                                                                                                                                                  
  *Escherichia coli* LMP0101U\                                       MIC = 39.06 µg/ml except for *P. mirabilis* (78.12 µg/ml)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  *Morganella morganii* LMP0904G\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  *Proteus mirabilis* LMP0504G *Staphylococcus aureus* LMP0206U\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  *Bacillus stearothermophilus* LMP0104G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                     *Candida albicans*                                          IZ = 14.5 mm\                                                                                                                                                                                                                                                                                                                                                                    Growth inhibition                                                                                                                                                                                                                                       [@B59]
                                                                                                                                 MIC = 78.12 µg/ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  *Candida albicans* wild type\                                      MIC = 0.25 µg/ml\                                           Growth inhibition                                                                                                                                                                                                                                                                                                                                                                [@B5]                                                                                                                                                                                                                                                   
  *Candida albicans* ATCC18804                                       MIC = 0.50 µg/ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  3D structure of CdsD protein of Chlamydial T3SS                                                                                Interaction with the active site residue GLU-626(O-H) of contact-dependent secretion D (CdsD) protein                                                                                                                                                                                                                                                                            [@B114]                                                                                                                                                                                                                                                 

  *Bacillus subtilis* ATCC6051\                                      MIC of 3.9 µg/ml except for *B. subtilis* (7.8 µg/ml)       Growth inhibition                                                                                                                                                                                                                                                                                                                                                                [@B18]                                                                                                                                                                                                                                                  
  *Staphylococcus aureus* ATCC12600\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  *Klebsiella pneumoniae* ATCC 13883\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Escherichia coli* ATCC11775                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *Staphylococcus aureus* SA1199B\                                   MIC = 64 µg/ml\                                             Growth inhibition                                                                                                                                                                                                                                                                                                                                                                [@B137]                                                                                                                                                                                                                                                 
  *Staphylococcus aureus* RN4220\                                    MIC = 128 µg/ml\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Staphylococcus aureus* EMRSA-15\                                  MIC = 128 µg/ml\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Staphylococcus aureus* XU212\                                     MIC \> 128 µg/ml\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  *Staphylococcus aureus* EMRSA-16\                                  MIC \> 128 µg/ml\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  *Staphylococcus aureus* ATCC25923                                  MIC \> 128 µg/ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Antimicrobial activity                                             *Staphylococcus aureus* MSSA\                               MIC = 15 µg/ml\                                                                                                                                                                                                                                                                                                                                                                  Growth inhibition                                                                                                                                                                                                                                       [@B1]
                                                                     *Staphylococcus aureus* MRSA\                               MIC = 30 µg/ml\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                     *Staphylococcus aureus* MDRSA                               MIC = 30 µg/ml                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Anticancer activity                                                KB oral epidermoid carcinoma cells                          ED~50~ = 4.13 µg/ml                                                                                                                                                                                                                                                                                                                                                              Inhibition of cell proliferation                                                                                                                                                                                                                        [@B95]

  P-388 leukemia cells                                               IC~50~ = 4.31 µg/ml                                         Inhibition of cell proliferation                                                                                                                                                                                                                                                                                                                                                 [@B126]                                                                                                                                                                                                                                                 

  HL-60, MOLT-4, K-562 leukemia cells                                50 µM                                                       Inhibition of cell proliferation; induction of apoptosis *via* both intrinsic and extrinsic pathways (activation of caspase-3, -8, -9; PARP cleavage; release of cytochrome c, Bax; downregulation of Bcl-2 expression) and inhibition of NF-kB (p65)/Stat3 tango in HL-60 cells                                                                                                 [@B61]                                                                                                                                                                                                                                                  

  Full NCI 60 cell panel                                             10^−5^ M                                                    Inhibition of proliferation of CCRF-CEM, MOLT-4, and HL-60(TB) leukemia cells, SN12C renal cancer cells and MCF7 breast cancer cells                                                                                                                                                                                                                                             [@B3]                                                                                                                                                                                                                                                   

  H2108, H1299, MRC-5 lung cancer cells;\                            30, 60 µM                                                   Inhibition of cell viability; induction of apoptosis (activation of caspase 3/7; repression of AP-1 and NF-kB-dependent transcription; inhibition of ERK/MAPK pathway);\                                                                                                                                                                                                         [@B89]                                                                                                                                                                                                                                                  
  LPS-stimulated RAW264.7 cells                                                                                                  Suppression of (LPS)-induced NO productiwn                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Eca109, KYSE30 esophageal squamous carcinoma cells (ESCC);\        5, 10, 20 µM;\                                              Inhibition of cell proliferation; increase in radio-sensitivity of ESCC; enhanced irradiation-induced DNA damage, apoptosis, G2/M cell cycle arrest; increase in irradiation-induced ROS generation by suppressing Nrf2 and target genes HO-1 and NQO-1; *in vivo* suppression of tumor growth and expression of Ki-67 and PCNA; more profound in combination with irradiation   [@B148]                                                                                                                                                                                                                                                 
  Eca109 xenograft mouse model                                       20 mg/kg daily for 20 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                     786-O, RCC4 clear-cell renal cell carcinoma (ccRCC);\       2.5, 5, 10 µM;\                                                                                                                                                                                                                                                                                                                                                                  Suppression of cell growth; induction of apoptosis; inhibition of cell invasion; increased miR-101 expression; repression of RLIP76 expression; inhibition of Akt *in vivo* suppression of tumor growth and pulmonary metastasis                        [@B138]
                                                                     786-O xenograft mouse model                                 40, 80 mg/kg daily for 24 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  HCT-116, SW480 colorectal cancer (CRC) cells;\                     5, 10 µM;\                                                  Inhibition of cell proliferation; induction of apoptosis; increased DNA double-strand breaks by inhibiting DNA repair *via* RAD51 downregulation; suppression of CRC tumor growth without adverse effects on normal tissues; downregulation of *in situ* levels of Ki-67, Bcl-2 and RAD51; increased cleaved caspase-3 and Bax in tumor tissues                                  [@B70]                                                                                                                                                                                                                                                  
  HCT-116 xenograft mouse model                                      25, 50 mg/kg daily for 24 days i.p.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  PC-3 prostate cancer cells                                         IC~50~ \> 30 µM                                             Inhibition of cell proliferation                                                                                                                                                                                                                                                                                                                                                 [@B91]                                                                                                                                                                                                                                                  

  Anticancer activity                                                A375, SK-MEL-1 melanoma cells;\                             5, 10 µM;\                                                                                                                                                                                                                                                                                                                                                                       Inhibition of cell proliferation; impaired metastatic potential by downregulating COX-2 via the miR-124/SPHK 1 axis; decreased number of lung metastases; decreased COX-2 and SPHK1 expression and increased miR-124 expression in metastatic tissues   [@B41]
                                                                     B16-F10 mouse model of lung metastasis                      20, 50 mg/kg daily for 24 days (intragastric route)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  EC9706, KYSE30 ESCC cell lines;\                                   10, 20 µM;\                                                 Suppression of cell proliferation and tumor growth;\                                                                                                                                                                                                                                                                                                                             [@B44]                                                                                                                                                                                                                                                  
  KYSE30 xenograft mouse model                                       50, 100 mg/kg daily for 30 days                             Induction of apoptosis by upregulating the miR-370/PIM1 signaling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  CCRF-CEM, CEM/ADR5000 leukemia cells                                                                                           Strong inhibition of cell proliferation (degree of resistance = 0.62); induction of G0/G1 cell cycle arrest and apoptosis in CCRF-CEM cells through caspase 3/7 activation, mitochondrial membrane potential loss, and ROS production                                                                                                                                            [@B58]                                                                                                                                                                                                                                                  

  MDA-MB-231-pcDNA3, MDA-MB-231- BCRP clone 23 breast cancer cells                                                               Moderate inhibition of cell proliferation (degree of resistance = 1.54)                                                                                                                                                                                                                                                                                                          [@B58]                                                                                                                                                                                                                                                  

  HCT116 (*p*53^+/+^), HCT116 (*p*53^−/−^) colon cancer cells                                                                    Moderate inhibition of cell proliferation (degree of resistance = 0.86)                                                                                                                                                                                                                                                                                                          [@B58]                                                                                                                                                                                                                                                  

  U87MG, U87MG.Δ*EGFR* glioblastoma cells                                                                                        Moderate inhibition of cell proliferation (degree of resistance = 0.90)                                                                                                                                                                                                                                                                                                          [@B58]                                                                                                                                                                                                                                                  

  T47D, MDA-MB-231 breast cancer cells                               1, 3, 10 µM                                                 Inhibition of hypoxia-induced and iron chelator-induced HIF-1 activation in T47D cells; inhibition of MDA-MB-231 cell migration and chemotaxis                                                                                                                                                                                                                                   [@B75]                                                                                                                                                                                                                                                  

  Antidiabetic activity                                              α-glucosidase                                               IC~50~ = 73.3 µM                                                                                                                                                                                                                                                                                                                                                                 Inhibition of α-glucosidase activity                                                                                                                                                                                                                    [@B40]

  Protein tyrosine phosphatase-1B (PTP1B)                            IC~50~ = 42.0 µM                                            Inhibition of PTP1B activity                                                                                                                                                                                                                                                                                                                                                     [@B88]                                                                                                                                                                                                                                                  

  PTP1B                                                              IC~50~ = 21.2 µM                                            Inhibition of PTP1B activity                                                                                                                                                                                                                                                                                                                                                     [@B129]                                                                                                                                                                                                                                                 

  L6 myotubes; PTP1B                                                 1, 10, 25 µM                                                Stimulation of basal and insulin-treated glucose-uptake in L6 myotubes by increasing AMPK activation, glucose transporters mRNA expression; moderate inhibition of PTP1B (IC~50~ = 37.52 µM)                                                                                                                                                                                     [@B66]                                                                                                                                                                                                                                                  

  Acyl-CoA:diacylglycerol acyltransferase (DGAT)                     12.5 µg/ml                                                  Inhibition of DGAT activity                                                                                                                                                                                                                                                                                                                                                      [@B100]                                                                                                                                                                                                                                                 

  Neuroprotective activity                                           Monoamine oxidases (MAOs)                                   IC~50~ = 25.8, 52.6, 16.8 µM, respectively                                                                                                                                                                                                                                                                                                                                       Inhibition of mixed mouse total brain MAO, MAO-A and MAO-B activity                                                                                                                                                                                     [@B43]

  SH-SY5Y neuroblastoma cells                                        IC~50~ \> 25 µM                                             Attenuation of 6-hydroxydopamine-induced neurotoxicity and ROS generation                                                                                                                                                                                                                                                                                                        [@B57]                                                                                                                                                                                                                                                  

  Antiplasmodial activity                                            *Plasmodium falciparum*                                     IC~50~ = 1.98 µg/ml                                                                                                                                                                                                                                                                                                                                                              Inhibition of parasite proliferation                                                                                                                                                                                                                    [@B127]

  Anti-HIV                                                           HIV-1 protease                                              IC~50~ = 30.1 µM                                                                                                                                                                                                                                                                                                                                                                 Inhibition of HIV-1 protease activity                                                                                                                                                                                                                   [@B65]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Akt, protein kinase B; BV/TV ratio, bone volume/total volume ratio; cMyc, myelocytomatosis viral oncogene homolog; COX-2, cyclooxygenase-2; DPPH, l,l-diphenyl-2-picrylhydrazyl; ER, estrogen receptor; ERK, extracellular signal-regulated kinase; GREB1, growth regulation by estrogen in breast cancer 1; HIF-1, hypoxia-inducible factor-1; HO-1, heme oxygenase-1; ICAM-1, intercellular adhesion molecule-1; IZ, inhibition zone; JNK, c-Jun N-terminal kinases; LRH-1, liver receptor homologue 1; MAPKs, mitogen-activated protein kinases; MIC, minimum inhibitory concentration; NF-κB, nuclear factor-kappa B; NLRP3, nucleotide-binding domain-like receptor protein 3; NQO-1, NADPH:quinoneoxidoreductase-1; PARP; poly-ADP Ribose polymerase; PCNA; proliferating cell nuclear antigen; PIM1; Pim family kinases 1; RANKL; receptor activator of nuclear factor kappa-B ligand; ROS, reactive oxygen species; SPHK1, sphingosine kinase 1; Tb.N, trabecular number (linear bone density of the trabecular bone); Tb.Sp, trabecular separation (distance between the edges of the trabecular bone); Tb.Th, trabecular thickness.

Estrogenic and Antiestrogenic Activities {#s2_1}
----------------------------------------

Estrogenic plant-derived products act *via* binding to human estrogen receptors (ERs). AIF was found to be a weak ERα and ERβ binder with conflicting results concerning the preference for ERβ versus ERα ([@B33]; [@B78]; [@B85]). The authors used the same estrogen receptor competitor assay based on fluorescence polarization in the same laboratory and according to the instructions of the same manufacturer. The discrepancies can probably be ascribed to the purity of compound. The ER competitive ligand binding assay cannot distinguish between estrogenic and antiestrogenic substances and does not provide insight into the ability of a substance to initiate the molecular cascade leading to altered gene expression ([@B67]). To overcome this disadvantage, reporter gene assays such as the ER-mediated chemically activated luciferase gene expression assay (ER-CALUX) and the yeast estrogen screen (YES) based on stably transfected cell lines are usually applied. In an ER-CALUX assay using human osteosarcoma U2OS cells stably transfected with ERα and transiently transfected with ERβ, AIF stimulated the endogenous ER-estrogen response element (ERE) interaction and, thus, the luciferase reporter gene activity ([@B33]; [@B78]). However, in a yeast two-hybrid β-galactosidase assay, AIF failed to induce the ligand-dependent interaction of ERα and coactivator TIF2 as determined by the expression of a reporter gene, β-galactosidase ([@B102]). Although ER-CALUX and YES assays rely on the same principle and use the same receptors, the yeast cell wall is usually less permeable to compounds compared to mammalian cell membranes ([@B67]). This makes the ER-CALUX assay robust, more sensitive and more predictable than the YES assay ([@B69]). In MCF-7 cells, AIF upregulated ERα target genes such as proliferating cell nuclear antigen (PCNA), cyclin D1, cyclin E1, cMyc (myelocytomatosis viral oncogene homologue), and liver receptor homologue 1 (LRH-1), and downregulated growth regulation by estrogen in breast cancer 1 (GREB1) ([@B78]). On the other hand, AIF suppressed estradiol (E2)-induced activity in U2OS-ERβ cells but not in U2OS-ERα cells and ERα yeast two-hybrid systems ([@B102]; [@B78]). Antagonizing the ERβ-mediated signaling pathway in the presence or absence of E2 is not promising as ERβ is known to counteract the proliferative responses of ERα involved in estrogen-related cancers, osteoporosis, and cardiovascular diseases.

In *in vivo* studies AIF induced estrogen-like effects by increasing uterine wet weight as well as uterine and vaginal epithelial height in ovariectomized Wistar rats ([@B86], [@B85]). In this model, AIF also reduced the hot flush index by increasing the FSH/LH ratio. It displayed atheroprotective effects by an augmentation of HDL-cholesterol levels, a reduction in the atherogenic index of plasma ([@B86]), and by upregulating the expression of estrogen-sensitive genes associated with bile acid formation (Cyp7a1) ([@B87]). Taken together, the *in vitro* and *in vivo* systems/models used to study estrogenic effects of AIF are quite suitable. The investigations demonstrated that AIF, through activation of ERs and modulation of estrogen-sensitive genes, exhibited estrogenic activities on uterus and vagina and by influencing several factors reduced the atherogenic risk. Nevertheless, further *in vivo* studies are necessary to get deeper insight into its potential.

Antiosteoporotic Activity {#s2_2}
-------------------------

Isoflavonoids are increasingly considered as a promising first-line prophylaxis for osteoporosis in clinical settings ([@B77]; [@B62]). The therapeutic strategies globally emphasize the inhibition of "osteoclast-mediated bone resorption" and/or the prevention of the apoptosis of osteoblasts and osteocytes.

Using experimental protocols of postmenopausal or glucocorticoid-induced osteoporosis, AIF exhibited an antiosteoporotic activity both *in vitro* and *in vivo*. A 6-week oral treatment with AIF (10 and 25 mg/kg) prevented ovariectomy-induced osteoporosis in mice by suppressing osteoclast differentiation ([@B28]). Despite its limits ([@B35]; [@B68]), the ovariectomized rat/mouse model is the most widely used animal model in research on postmenopausal osteoporosis. Long-term exposure to glucocorticoids, e.g., in the treatment of chronic autoimmune and pulmonary disorders, cancers of the lymphoid system, as well as in the prevention of transplant rejection ([@B98]), is the primary cause of the secondary osteoporosis ([@B125]). In dexamethasone-induced osteoporosis in rats, 20 and 40 mg/kg AIF p.o. prevented bone loss ([@B139]). *In vitro*, 5--20 µM AIF abrogated the dexamethasone-induced cytotoxicity and proapoptotic effects on osteoblasts and osteocytes (MC3T3-E1 and MLO-Y4 cells) through the inhibition of ROS production as well as through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) and AMPK-dependent NAD(P)H oxidase 2 (Nox2) signaling pathways ([@B139]; [@B147]). Osteoporosis remains an important target of research ([@B46]), and, despite some limits, the two described animal models are appropriate and closer to the human situation than other models. Although further investigation is needed, the available studies showed that AIF, by suppressing osteoclast differentiation or osteoblasts and osteocytes apoptosis, could have beneficial effects on postmenopausal- and glucocorticoid-induced bone damage.

Antioxidant and Anti-Inflammatory Activities {#s2_3}
--------------------------------------------

Through free radical-scavenging and antioxidative effects, antioxidants constitute the first line of defense against the pathogenesis of several diseases ([@B108]).

AIF showed radical scavenging activity against l,l-diphenyl-2-picrylhydrazyl (DPPH) radicals ([@B107]; [@B11]; [@B126]; [@B1]; [@B40]). IC~50~ values of 8.30 μg/ml ([@B107]), 54.02 μg/ml ([@B11]), 54.80 μM ([@B40]), and 708.50 μM ([@B126]) were determined. In lipopolysaccharide (LPS)-stimulated murine macrophages RAW264.7 and in mice with LPS-stimulated acute lung injury (ALI), 5 and 10 µg/ml AIF significantly increased the production of antioxidative enzymes such as catalase, heme oxygenase-1 (HO-1), glutathione peroxidase, and superoxide dismutase ([@B71]).

There is a long and ever-growing list of *in vitro* antioxidant assays. In the DPPH free radical scavenging assay, quite different IC~50~ values were obtained with AIF probably due to the differences in assay conditions ([**Table 3**](#T3){ref-type="table"}). Variable DPPH concentrations, incubation times, sample volumes, solvent systems, and pH clearly result in large differences in IC~50~ values (reviewed by [@B124]). To standardize the methodology and ensure comparability between studies or laboratories, a DPPH concentration of 50 µM (for good accuracy), an incubation time of 30 min, and methanol as solvent for less polar samples or buffered methanol for more polar samples have been proposed ([@B117]; [@B83]). Results expressed in different units additionally impede cross-comparison in many cases. The DPPH assay does not actually measure the antioxidant activity but the reducing capacity of the sample ([@B8]). Moreover, there is no linear relationship between the antioxidant concentration and the radical scavenging activity. The numerous drawbacks of this assay underline its ineptitude to evaluate the antioxidant capacity. Among the other single electron transfer (SET)-based assays such as the trolox equivalent antioxidant capacity (TEAC), ferric reducing antioxidant power (FRAP), and thiobarbituric acid reactive substances (TBARS), TEAC assay is most popular due to its convenient application which better reflects the antioxidant activity ([@B39]). More recently, hydrogen atom transfer (HAT)-based assays like oxygen radical absorbance capacity (ORAC), total radical-trapping antioxidant parameter (TRAP), and crocin-bleaching assays provide better analogies to *in vivo* action ([@B106]). The main limits of TRAP (which relies only on the lag phase of the kinetic curve for quantitation) and the crocin-bleaching (easily disturbed by compounds absorbing at the monitored wavelength of 450 nm, crocin is not sold as pure compound but as an extract of saffron) assays are probably the reason why the ORAC assay is currently preferred in food and pharmaceutical industries ([@B51]; [@B19]; [@B105]). According to [@B124], a mix of SET and HAT-based assays, encompassing several different radical types is recommended to better estimate the overall antioxidant activity of a sample. In summary, the DPPH assay is not appropriate to evaluate the antioxidant activity of a sample. Moreover, the studies recorded in this review did not use the standardized protocols. However, results from the LPS-induced ALI protocol, well known to be associated with the production of ROS and oxidative stress ([@B122]; [@B146]), indicate that, *via* an activation of antioxidative enzymes, AIF could be beneficial in the treatment of diseases associated with oxidative stress.

###### 

Assay conditions of the DDPH method in studies recorded in this review.

  Studies   DPPH concentration   Solvent for sample (pH)                    Sample volume   Incubation time (min)   Standard compound
  --------- -------------------- ------------------------------------------ --------------- ----------------------- -------------------------------
  [@B11]    400 µM               Methanol (--)                                              30                      Quercetin
  [@B40]    --                   --                                         --              --                      Propyl gallate
  [@B107]   20 mg/l              Methanol (--)                                              20                      *Tert*-butyl-1-hydroxytoluene
  [@B126]   500 µM               Methanol + 0.1 M buffer acetate (pH 5.5)   --              30                      Ascorbic acid

--, not indicated.

The overproduction of free radicals is usually associated with excessive or sustained inflammatory reactions ([@B31]). Administered 1 h before LPS challenge, AIF (10 mg/kg i.p.) alleviated LPS-induced lung lesions, pulmonary edema, and hemorrhages by reducing the activity of myeloperoxidase ([@B71]). In this model and in LPS-induced RAW264.7 cells, 5 and 10 µg/ml AIF inhibited the production of proinflammatory mediators including tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1b, intercellular adhesion molecule-1 (ICAM-1), and nitric oxide (NO). The mechanisms underlying these activities include the suppression of nuclear factor-kappa B (NF-κB), mitogen-activated protein kinases (MAPKs), the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome, and IL-17 signaling pathways ([@B71]). A similar effect on LPS-induced NO production in RAW264.7 cells was observed by [@B89] with an IC~50~ value of 15.97 µM. In GOLD docking fitness, AIF displayed a fitness score of 35.42 against cyclooxygenase (COX)-2, an inducible enzyme only expressed after an inflammatory stimulus ([@B130]). Four hours after administration, AIF (25 mg/kg i.p.) reduced the carrageenan-induced rat paw edema by 29% in male Wistar rats, whereas the positive control indomethacin (10 mg/kg i.p.) reduced it by 41.67% ([@B3]). The models used in studies recorded in this review including the carrageenan-induced rat paw edema and the LPS-induced ALI are well-established to study the anti-inflammatory potential of chemicals. Therefore, results from these models provide a strong evidence of the anti-inflammatory potential of AIF.

Antimicrobial Activity {#s2_4}
----------------------

Over the last decade, the antimicrobial properties of AIF have been evaluated against several drug-resistant and drug-susceptible strains using agar disk diffusion ([@B59]), broth microdilution ([@B59]; [@B18]; [@B137]; [@B5]) and macrodilution assays ([@B113]), thin layer chromatography (TLC) bioautography ([@B1]), and computer-based (virtual) ([@B114]) methods.

Tuberculosis (TB) is the leading human infectious-related cause of death ([@B142]). Usually, nonpathogenic mycobacterial species such as *Mycobacterium smegmatis* are used as model systems ([@B2]; [@B90]). *M. smegmatis* displays an identical susceptibility to that of multidrug-resistant (MDR) clinical isolates of *Mycobacterium tuberculosis* for the two frontline anti-TB drugs isoniazid and rifampicin ([@B14]). AIF displayed a minimum inhibitory concentration (MIC) of 19.53 μg/ml and a minimum bactericidal concentration (MBC) of 39.06 μg/ml against *M. smegmatis* MC2 155 (32-fold less active than ciprofloxacin) while showing no activity against *M. smegmatis* ATCC14468 ([@B113]) and *M. tuberculosis* H37Rv ([@B59]).

AIF also prevented the growth of Gram-negative (*Enterobacter cloacae*, *Escherichia coli*, *Morganella morganii*, and *Proteus mirabilis*) and Gram-positive (*Staphylococcus aureus* and *Bacillus stearothermophilus*) bacteria with inhibition zones (IZ) of 15.5--18.5 mm. Only the effects against *E. coli* (IZ = 7.0 mm) were weaker. MIC values of 39.06 μg/ml (against *E. cloacae*, *M. morganii*, *S. aureus*, and *B. stearothermophilus*) and an MBC of 78.12 μg/ml (only against *M. morganii*) were determined. In this series, AIF was less active than the reference gentamycin (IZ = 23.8--31.7 mm; MIC = 2.44--9.76 μg/ml) ([@B59]). In a study by [@B18], AIF displayed MICs of 3.9 μg/ml (against *S. aureus*, *E. coli*, and *Klebsiella pneumoniae*) and 7.8 μg/ml (against *Bacillus subtilis*), while those of the reference neomycin ranged between 0.78 and 1.6 μg/ml. Weak inhibitory activity (MIC ≥ 64 μg/ml) was observed against drug-resistant (SA1199B, RN4220, EMRSA-15, XU212, and EMRSA-16) and wild-type strains of *S. aureus* ([@B137]). Using a TLC bioautography assay, [@B1] reported minimum inhibitory quantities of 15 μg for methicillin-sensitive *S. aureus* and 30 μg for a methicillin-resistant and an isolated multidrug resistant strain of *S. aureus*. By contrast, AIF did not show antibacterial activity against the clinical isolates of *S. aureus*, *M. morganii*, *E. coli*, and *Klebsiella granulomatis* in a study by [@B113]. This might be explained by differences in the methods and microbial strains.

*Chlamydia trachomatis* is the most common infectious cause of trachoma. By significantly interacting (G.score of --2.5 kcal/mol) with the active site residue GLU-626(O-H) of contact-dependent secretion D (CdsD) protein *in silico*, AIF might disrupt the assembly of the type III secretion system (T3SS) involved in differentiation, replication, and dissemination *C. trachomatis* ([@B114]).

AIF was fungistatic against wild (MIC = 0.25 μg/ml) and ATCC18804 (MIC = 0.50 μg/ml) strains of *Candida albicans* ([@B5]). At the concentration of 50 μg/ml, AIF was not able to inhibit the activity of fatty acid synthase (a potential antifungal target) and the growth of *C. albicans* ATCC90028 and *Cryptococcus neoformans* ATCC90113 ([@B73]). It did not display any activity against *Candida glabrata* ([@B59]).

The antibacterial activity of flavonoids is often widely conflicting mainly due to the use of different nonstandardized techniques. To overcome this issue, the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial susceptibility testing (EUCAST) have approved and published some guidelines over the last two decades ([@B23]; [@B26]; [@B20]; [@B27]; [@B21]; [@B22]; [@B25]; [@B24]; [@B37]; [@B38]). However, despite these guidelines for agar dilution, broth microdilution, and broth macrodilution, results from nonstandardized protocols are still published even in highly reputable journals. Although the disk diffusion technique is easy to apply without specialized equipment, and cheap, the determined IZ value is not related to the antibacterial activity but depends on polarity, concentration, and molecular weight of compounds ([@B124]). Thus, highly polar compounds display a high IZ, and many compounds with the same diffusion rate result in quite different antimicrobial activities. This method is only useful for a simple qualitative screening. It does not allow the quantification of the amount of the antimicrobial agent diffused into the agar, impeding the determination of MICs and MBCs ([@B93]; [@B6]). The broth macrodilution or microdilution assays are among the most appropriate methods to determine MIC and MBC values despite the fact that they are unsuitable for highly nonpolar compounds ([@B124]). The reproducibility and the low price due to small amounts of reagents are the main advantages of the microdilution assay over the macrodilution assay. The latter is tedious to perform, requires a lot of manual handling, and is associated with a risk of errors in the preparation of antimicrobial solutions ([@B54]). Accordingly, the microdilution method appears to be more accurate. In general, the interpretation of the efficacy depends on the profound knowledge of the model and the used protocol. Nevertheless, stringent endpoint criteria have been set to MIC values of \<10 µg/ml or \<25 µM for promising plant compounds ([@B111]; [@B29]). According to this criterion, AIF could be considered promising only against *S. aureus* ATCC12600, *E. coli* ATCC11775, *K. pneumonia* ATCC13883, *B. subtilis* ATCC6051, and wild and ATCC18804 strains of *C. albicans*. Overall, despite the limits of the used assays/protocols and the discrepancies in results, recorded data suggest the potential of AIF to act as an antimicrobial drug against few microorganisms.

Anticancer Activity {#s2_5}
-------------------

Different studies reported promising anticancer activities of plant-derived (iso)flavonoids ([@B79]; [@B96]; [@B103]) including the suppression of proliferation, migration/invasion, tumor angiogenesis and metastasis, and the promotion of apoptosis in various cancers.

In several studies the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was applied to determine the cytotoxic effects of AIF: The compound exhibited strong cytotoxicity against human oral epidermoid carcinoma KB cells (IC~50~ = 4.13 μg/ml) ([@B95]) and murine leukemia P-388 (IC~50~ = 4.31 μg/ml) cells ([@B126]). IC~50~ values of 19, 34, and 41 μM, respectively, were observed against human leukemia HL-60, K-562, and MOLT-4 cell lines ([@B61]). In human lung H2108, H1299, and MRC-5 cancer cell lines, AIF displayed moderate cytotoxicity with IC~50~ values of 33.5, 38.8, and 52.5 µM, respectively ([@B89]). At the concentration of 10 µM, the growth and invasion of the human clear-cell renal carcinoma ccRCC 786-O and Caki1 cells were suppressed by 40 and 50--60%, respectively ([@B138]). An IC~50~ value of \>25 μM was obtained against human prostate PC-3 ([@B91]) and neuroblastoma SH-SY5Y ([@B49]) cancer cells. At the concentration of 10^−5^ M, AIF inhibited the growth of the renal SN12C cancer cells by 32.67% ([@B3]). AIF (10 μg/ml) displayed a low antiproliferative activity (30--40% inhibition) against the human melanoma A375 and SK-MEL-1 cells after a 24-h incubation and suppressed the migration and invasion of these cell lines ([@B41]). However, after 48 h of incubation, AIF did not exhibit inhibitory effects against SK-MEL-28 cells in a study by [@B50]. The degree of cytotoxicity in MTT assay increases with the cell number, the concentration of MTT, and the incubation time ([@B132]). The concentration of MTT was not indicated in the two latter studies, and the cell number (5 × 10^3^ cells/well) was only indicated by [@B50]. Comparison of the incubation times showed that the higher incubation time ([@B50]) was associated with lower antiproliferative activity. Although neglected in the vast majority of studies, long incubation times are often associated with the decomposition, metabolism, or precipitation of compounds ([@B4]).

Under use of a cell counting kit-8 (CCK-8) assay, AIF exhibited a moderate antiproliferative activity against human esophageal squamous carcinoma (ESCC) Eca109 and KYSE30 cells and at 5 µM enhanced the sensitivity of these cell lines to irradiation ([@B148]). In the same model, it also reduced the viability of colorectal HCT-116 and SW480 cancer cells (IC~50~ of 10 and 5 µM, respectively) ([@B70]). The enzyme-based methods including CCK-8 and MTT assays are easy to use, safe, and have a high reproducibility. However, the toxicity of MTT as well as interference of polyphenols with the tetrazolium MTT dye has to be taken into consideration ([@B141]). A further advantage of the CCK-8 method is its far higher sensitivity (<https://www.dojindo.eu.com/Shared/Flyers/Flyer_CCK-8-Rev.pdf>)

At 10^−5^ M, AIF inhibited the growth of leukemia CCRF-CEM, MOLT-4, and HL-60 cancer cells by 51.17, 26.15, and 15.49%, respectively. In this study, the type of assay was not specified ([@B3]).

Induction of apoptosis is a very important property of anticancer drug candidates. In 786-O and Caki1 cells, AIF led to apoptosis by modulating the miR-101/RLIP76 signaling pathway through the inhibition of Akt ([@B138]). In addition to the induction of DNA damage and cell cycle arrest ([@B148]), AIF induced apoptosis in ESCC cells by upregulating the miR-370/Pim family kinases 1 (PIM1) signaling ([@B44]) and by suppressing the expression of Nrf2, HO-1 and NADPH:quinine oxidoreductase-1 ([@B148]). In HL-60 leukemia cells, apoptotic cell death was observed *via* the suppression of NF-κB and the signal transducer and activator of transcription (STAT) signaling pathway ([@B61]). AIF induced lung tumor apoptotic cell death by repressing both the ERK/MAPK and NF-κB pathways ([@B89]). In HCT-116 and SW480 cells, it triggered apoptosis by blocking DNA damage repair mediated by the DNA double-strand break repair gene RAD51 ([@B70]) and in CCRF-CEM cells through the loss of MMP and production of ROS ([@B58]).

Drug resistance constitutes a major impediment to effective cancer treatment. AIF displayed antiproliferative effects against several MDR cancer cell lines. Strong antiproliferative activities were obtained for both the drug-sensitive CCRF-CEM (IC~50~ = 9.6 μM) and the multidrug-resistant P-glycoprotein-overexpressing subline CEM/ADR5000 (IC~50~ = 5.91 μM) cells ([@B58]). In other drug-sensitive cell lines \[breast MDA-MB-231-pcDNA3, colon HCT116 (p53^+/+^), glioblastoma U87MG\] and their MDR counterparts \[MDA-MB-231-*BCRP* clone 23, HCT116 (p53^−/−^) and U87MG.*ΔEGFR*\], AIF displayed moderate effects with IC~50~ values of 42.4--46.7 and 36.4--65.6 μM, respectively. In comparison to normal AML12 hepatocytes, a selective index \>3.13 was observed towards HepG2 liver cancer cells ([@B58]).

The role of increased activity of hypoxia-inducible factor-1 (HIF-1), especially HIF-1α is well known in cancer progression ([@B81]; [@B115]). Hypoxic cancer cells seem to be resistant to radiation and chemotherapy ([@B112]; [@B149]). Therefore, targeting HIF-1 is an important approach for cancer prevention and treatment. AIF suppressed both hypoxia-induced and iron chelator-induced HIF-1 activation in T47D human breast cancer cells as well as MDA-MB-231 cell migration ([@B75]).

The antiproliferative or cytotoxic activity associated with apoptosis in malignant cells is a highly important target in the screening of anticancer drugs. Given the severe adverse reactions in normal tissues by tumoricidal doses of chemotherapeutic agents, the cytotoxic activity of drug candidates should also be evaluated against normal cells. In addition to a strong antiproliferative activity (IC~50~ \<4 µg/ml or \<10 µM for a pure compound after 48--72 h incubation) ([@B10]), a high selectivity (selectivity index ≥3) towards malignant cells is needed. The inclusion of positive controls in respective studies of natural compounds is indispensable in good experimental practice ([@B4]). Among the 13 *in vitro* studies recorded in this review, only one investigated the effects against normal cells ([@B61]) and four used a positive control ([@B91]; [@B126]; [@B50]; [@B49]). In addition to this deficit, human tumor cell lines as the workhorse of cancer research are cultured since decades and do not adequately mirror (different tumor environment) the biology of human tumors ([@B7]). Therefore, *in vivo* models with better and more clinically predictive power of human cancers are an imperative.

*In vivo*, AIF has been tested in various xenograft mouse models. After 30 consecutive days of treatment, the compound reduced tumor growth in KYSE30 (50 and 100 mg/kg/day) and Eca109 (20 mg/kg/day) xenograft mouse models ([@B44]; [@B148]). It also suppressed the tumor growth in an HCT-116 xenograft mouse model after 24 days treatment (25 and 50 mg/kg/day AIF i.p.) ([@B70]). In a B16-F10 mouse lung model of metastasis, 24-day intragastrical administration of 20 and 50 mg/kg/day AIF decreased the number of metastatic pulmonary nodules. The reduction in COX-2 through modulating miR-124/SPHK1 axis was the underlying mechanism involved ([@B41]). The dose of 40 and 80 mg/kg/day for 24 days suppressed the growth and pulmonary metastatic nodules in a 786-O xenograft mouse model by modulating miR-101/RLIP76 signaling ([@B138]). In a study by [@B148], combination of AIF (20 mg/kg/day for 30 days) with irradiation induced a more profound tumor regression than single treatments. All these *in vivo* activities occurred without affecting the body weight of the mice. Despite the drawbacks of the majority of the current cell-line-derived or patient-derived mouse xenograft models reviewed by [@B63], they have become a prominent cancer model system over decades. For research in pharmaceutical industry, the accurate description of materials and methodology is indispensable to assure that experiments can be accurately replicated. However, the route of administration of AIF, an extremely important parameter, is not mentioned in the studies by [@B148] and [@B138], published in "high-impact" journals. As a different route of administration leads to different results, this underlines the importance of an accurate review of such papers. Nevertheless, all data reported in this section demonstrate that AIF could have a potential to suppress some tumor growth *in vivo*.

Antidiabetic Activity {#s2_6}
---------------------

Adequate glycemic control remains the main foundation of managing diabetes mellitus (DM) ([@B15]). Retarding the release of D-glucose from dietary carbohydrates and delaying its absorption through the inhibition of α-glucosidase is an attractive therapeutic target for the treatment of DM, obesity, and other related complications ([@B131]). *In vitro*, AIF exhibited a moderate α-glucosidase inhibitory activity with an IC~50~value of 73.3 ± 12.9 μM ([@B40]).

Protein tyrosine phosphatase 1B (PTP1B) is a negative key regulator of insulin signaling pathways that leads to insulin resistance. Thus, it is a promising molecular-level therapeutic target in the management of type 2 DM and obesity ([@B136]). In a study by [@B88], AIF exhibited *in vitro* PTP1B inhibitory activity with an IC~50~ value of 42 μM as compared to the positive controls RK-682 (IC~50~ = 4.5 ± 0.5 μM) and ursolic acid (IC~50~ = 3.6 ± 0.2 μM) ([@B129]). By increasing the AMPK activation and the expression of glucose transporters' (GLUT-4 and -1) mRNA as well as by inhibiting the PTP1B activity (IC~50~ = 37.52 µM vs. ursolic acid---5.13 µM), AIF significantly stimulated the glucose uptake in L6 myotubes ([@B66]). These differences in IC~50~ values can be explained by the application of different experimental conditions. Using a nonkinetic method to estimate the amount of produced *p*-nitrophenol at 405 nm, [@B88] added 10 M NaOH to stop the reaction, while in the study of [@B129], the release rate of *p*-nitrophenol (kinetic method) was determined by measuring the absorbance at 405 nm every 30 s for 10 min. Moreover, these studies used different concentrations of PTP1B and the substrate *p*-nitrophenyl phosphate.

Acyl-CoA:diacylglycerol acyltransferase (DGAT) is a key enzyme in the synthesis of triglycerides, the imbalance of which usually leads to insulin resistance and type 2 DM. At the concentration of 12.5 μg/ml, AIF induced 23% inhibition of the activity of this enzyme, while the positive control displayed an IC~50~ value of 4.8 µg/ml ([@B100]).

Overall, these preliminary results suggest that AIF could exhibit a potential for the treatment of type 2 DM by retarding the glucose absorption from small intestine, by increasing the insulin sensitivity and the glucose transport into cells, and by improving triglycerides' profile. But most important, this hypothesis has to be confirmed by respective meaningful *in vivo* models.

Neuroprotective Activity {#s2_7}
------------------------

Elevation of the activity of brain monoamine oxidases (MAOs), especially MAO-B, contributes to chronic neurodegeneration and brain atrophy ([@B92]; [@B128]). AIF inhibited the mixed type of mouse total brain MAO with an IC~50~ value of 25.8 μM. Its activity on MAO-B (IC~50~ = 16.8 μM) was 3.1-fold higher than that on MAO-A ([@B43]). Globally, AIF was more active than the positive control amitriptyline on mixed MAO, MAO-A, and MAO-B. By destroying dopaminergic and noradrenergic neurons in the brain through excessive production of ROS such as superoxide radicals, the neurotoxin 6-hydroxydopamine (6-OHDA) induces neuronal cell death and Parkinson's disease in rats ([@B45]; [@B104]; [@B116]). At noncytotoxic concentrations, AIF attenuated (IC~50~ \> 25 μM) the 6-OHDA-induced neurotoxicity and ROS generation in SH-SY5Y cells ([@B57]).

The relatively high MAO inhibitory activity of AIF compared to amitriptyline and its capacity to protect against 6-OHDA-induced neurotoxicity justifies further in-depth investigations of AIF for its potential in neurodegenerative diseases such as Parkinson's and Alzheimer's.

Other Activities {#s2_8}
----------------

With 216 million cases and 445,000 deaths in 2016, malaria remains a major cause of death worldwide, especially in Africa (<http://www.who.int/malaria/en/>). AIF has shown strong antiplasmodial properties against *Plasmodium falciparum* with an IC~50~ value of 1.98 µg/ml as compared with the positive control chloroquine (IC~50~ = 1.02 µg/ml) ([@B127]).

HIV-1 protease and reverse transcriptase are the most important targets in the search for anti-HIV agents. *In vitro*, AIF showed a low inhibitory activity against HIV-1 protease with an IC~50~ value of 30.1 μM ([@B65]).

Structure-Activity Relationship {#s3}
===============================

Numerous prenyl- ([@B50]), O-methyl- ([@B134]; [@B43]; [@B75]; [@B74]; [@B94]; [@B5]; [@B99]; [@B40]), and/or O-acetyl ([@B11]; [@B5]) derivatives of AIF have been detected in various plants and studied for the impact on the biological activities. From studies comparing both the activities of AIF and those of one or more of its derivatives ([**Table 4**](#T4){ref-type="table"}), it can be deduced that:

i.  The replacement of C4′-OH and/or C5-OH by −OMe or O-acetyl reduces the antifungal activity against *C. albicans* ([@B5]).

ii. The 4′-O-methylated form of AIF promoted the inhibition of HIF-1 activation in T47D cells, the MDA-MB-231 cell migration ([@B75]), and the inhibition of urease ([@B94]) and MAO-A ([@B43]) activities, while no significant changes on the influence on MAO-B and α-glucosidase activities were observed ([@B43]; [@B40]).

iii. In AIF, initially inactive, the introduction of a prenyl group at the C-8 position to obtain scandenolone or warangalone significantly increased the growth inhibitory activity (IC~50~ \< 5 μM) towards human melanoma SK-MEL-28 cells ([@B50]).

iv. The \[1, 2- *b*:5, 4- *b*'\] dipyran derivative derrone showed antiproliferative activity in human leukemia U937 cells in a similar magnitude like AIF ([@B82]). The same refers to the inhibition of PTP1 (IC~50~ = 12.6 µM for derrone and 21.6 µM for alpinumisoflavone) ([@B129]). In contrast, derrone was moderately inhibiting phospholipase Cγ1 activity and the formation of inositol phosphates in phospholipase Cγ1-overexpressing NIH3T3 fibroblasts, whereas AIF remained without effect ([@B101]).

###### 

Impact of different substitutions on the activity of alpinumisoflavone.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Substituent                                           Impact on the activity                                          Experimental model                                References
  ----------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------- ------------
  **4′-O-methyl**                                       ↑ Inhibition of hypoxia-inducible factor-1 (HIF-1) activation   Human breast tumor T47D cells                     [@B75]

  ↑ Inhibition of tumor cell migration and chemotaxis   MDA-MB-231 cells                                                [@B75]                                            

  ↓ Antiradical activity                                DPPH assay                                                      [@B40]                                            

  ↔Inhibition of α-glucosidase activity                 α-Glucosidase enzyme model                                      [@B40]                                            

  ↓ Antifungal activity                                 *Candida albicans* (wild and ATCC18804 strains)                 [@B5]                                             

  ↑ Monoamine oxidase-A (MAO-A) activity\               Mitochondrial fraction from mouse brain                         [@B43]                                            
  ↔ MAO-B activity                                                                                                                                                        

  ↑ Inhibition of urease activity                       *Helicobacter pylori* urease enzyme assay                       [@B94]                                            

  **O,O-dimethyl**                                      ↓ Antifungal activity                                           *Candida albicans* (wild and ATCC18804 strains)   [@B5]

  **5-O-acetyl- and 4′-O-methyl**                       ↓ Antifungal activity                                           *Candida albicans* (wild and ATCC18804 strains)   [@B5]

  **4´-O-acetyl**                                       ↓ Antiradical activity                                          DPPH assay                                        [@B11]

  **8-prenyl**                                          ↑ Antiproliferative activity                                    Human melanoma SK-MEL-28 cells                    [@B50]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑; increase, ↓; decrease, ↔; not different.

The differences in the activities of some compounds closely related to AIF, preclinically tested in comparable assays but not directly compared with AIF, are difficult to interpret due to the limitations as discussed above. Nevertheless, we include those results, which were obtained in the most similar experimental setups:

i.  The 2′-OH derivative parvisoflavone B showed a stronger α-glucosidase inhibition (IC~50~ = 12.2 µM; [@B32]) than AIF (IC~50~ = 73.3 µM; [@B40]). Nevertheless, due to the lack of a positive control in the study with AIF, a comparison of the results remains questionable. Parvisoflavone B resulted also in a better cytotoxic effect against MDA-MB-231 breast cancer cells (EC~50~ = 16.9 µM) ([@B97]). The weak antimycobacterial effect (MIC = 90.9 µM) of parvisoflavone B against *M. tuberculosis* H37rV) ([@B97]) differed from the inactive AIF ([@B59]).

ii. Cudraisoflavon M---carrying an additional 2,3-dihydroxy-prenyl group at C-8 of AIF---did not show any activity against 6-OHDA-induced cell death in SH-SY5Y cells ([@B48]), whereas cudraisoflavon H with a prenyl group at C-8 and an additional hydroxy group at C-2″ of AIF resulted in an IC~50~ value of 4.5 µM ([@B47]).

iii. The comparison of the antimicrobial effects of derrone with AIF is extremely difficult due to the differences in the experimental setup as discussed above. Nevertheless, the activity of derrone against *E. coli*, *S. aureus*, and *C. albicans* seems lower than the one of AIF ([@B36]). The antiproliferative potential of derrone and AIF differ in dependence of the cell line: In SW480 cells, AIF with an IC~50~ value of 5 µM inhibits the proliferation ([@B70]), whereas derrone remains inactive ([@B72]). In MCF-7 cells, AIF was inactive ([@B123]) and derrone at 10 µM inhibited this cell line by 13.6% ([@B72]). HepG2 cells seem to be similarly sensitive to the two compounds \[AIF---IC~50~ 37.99 µM ([@B58]); derrone---23.7% inhibition at 10 µM ([@B72])\].

iv. 2′-Hydroxyerythrin A with the OH group from C-5 shifted to C-2′ showed good activity against several Gram-positive and Gram-negative bacteria ([@B140]). The magnitude of the DPPH radical scavenging effect was in the same range ([@B140]) as in some studies with AIF ([@B107]; [@B11]; [@B40]).

The infrequence of studies and the low number of different substitution patterns and of investigated activities are the main drawback in the deduction of structure--activity relationships (SAR) of AIF and its derivatives. Continued efforts are needed to further synthesize or isolate new derivatives of AIF to expand SAR. Nevertheless, published data indicate that the C4′-O-methylation and the C8-prenylation increase the activity of AIF in cancer and neurodegenerative conditions. This is in accordance with [@B9] who indicated that O-methylation of flavonoids ensures a superior anticancer activity as compared with the corresponding hydroxylated derivatives, since such compounds are more resistant to hepatic metabolism and show higher intestinal absorption. In addition, [@B135] suggested that O-methylation enhances the stability of flavonoids to metabolic degradation and increases their bioavailability as well as a higher tissue distribution as compared to unmethylated forms.

Point of View and Future Perspective {#s4}
====================================

Prenylated (iso)flavonoids are attracting more and more attention due to a series of promising biological activities ascribed to their increased lipophilicity and a strong affinity to biological membranes as compared to the respective unprenylated compounds ([@B13]; [@B12]; [@B17]; [@B119]; [@B84]). In this context, numerous pharmacological investigations of alpinumisoflavone, extracted from various medicinal plants, were carried out over the last decades. Data recorded in this review evidence a wide array of activities such as antiosteoporotic, antioxidant, anti-inflammatory, antimicrobial, anticancer, estrogenic and antiestrogenic, antidiabetic, and neuroprotective. Discrepancies between results were usually attributed to the purity of the tested compound, the experimental setup, the operator's experience, or other experimental parameters ([@B4]). Many of related pathologies or conditions such as antimicrobial resistance, cancer, diabetes mellitus, and neurodegenerative diseases are becoming pivotal concerns for public health over the world. However, although AIF might be considered a promising preventive and/or therapeutic agent for such ailments, these investigations are only at the beginning. Using suitable and well-designed standardized models or assays, further and thorough studies related to the above mentioned or other pathologies/conditions are needed to confirm this potential. *In vitro* evaluation is an important primary screen and due to its rapidity common practice in many research laboratories. Nevertheless, many *in vitro* studies are not necessarily optimal due to poor standardization, redundancy, and/or outdated methodology ([@B124]). Clearly, compounds exhibiting promising activity require further studies to validate or confirm their therapeutic potential ([@B55]). Accordingly, the correlation with *in vivo* data using appropriate models is an indispensable prerequisite.

The analysis of structure--activity relationships provides information on the preferential conformation to maintain high activities. Studies of AIF until now revealed that the free --OH groups at C-4′ and C-5 are important for the fungicidal activity towards *C. albicans* ([@B5]). 4′-O-Methylation and the presence of a prenyl group at C-8 enhanced anticancer activities ([@B75]; [@B50]). Studies with diversified substituents would be ideal for the investigation of SARs. They might allow the identification of important structures with reduced toxicity and increased therapeutic efficacy that can guide the design of novel leads or drug candidates. However, such studies on AIF and its derivatives are scarce until now, and this underlines the necessity of further well-performed investigations.

Besides the efficacy, extensive safety and pharmacokinetic data are required for potential drug candidates as an important aspect in the drug development process. However, till today, no study dealing with the toxicity or pharmacokinetics of AIF has been reported.

Conclusion {#s5}
==========

This review evidences that AIF is a versatile compound with a wide array of possible health benefits. We summarize the current preclinical evidence of the antiosteoporotic, antioxidant and anti-inflammatory, antimicrobial, anticancer, estrogenic and antiestrogenic, antidiabetic, and neuroprotective activities ([**Figure 2**](#f2){ref-type="fig"}). However, more persuasive and scientific evidence and detailed mechanistic studies are urgently needed for a therapeutic exploitation of AIF. Moreover, SAR of AIF and its derivatives indicates that 4′-O-methyl-AIF appears to be more promising than AIF, and these indications need to be investigated in-depth.

![Overview over pharmacological activities of alpinumisoflavone and some of its derivatives.](fphar-10-00952-g002){#f2}
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